Literature DB >> 7505410

Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration.

H Tohgi1, T Abe, S Takahashi, J Takahashi, H Hamato.   

Abstract

In untreated patients with Parkinson's disease (PD), the total (free and conjugated) serotonin (5-HT) and dopamine (DA) concentrations in the cerebrospinal fluid decreased significantly. While the 5-HT concentration displayed a non-significant trend of negative correlation with the DA concentration in controls, it had a significant positive correlation with the DA concentration in untreated PD patients. In L-dopa-treated patients, the DA concentration increased remarkably, whereas the 5-HT concentration decreased further compared with untreated patients. The tryptophan, 5-hydroxyindolacetic acid (5-HIAA), and 3-OH kynurenine concentrations had significant positive correlations with L-dopa doses. The 5-HT concentration had a significant positive correlation with scores of psychomatric testing in L-dopa-treated patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505410     DOI: 10.1016/0304-3940(93)90817-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

2.  Bioanalytical inaccuracy: a threat to the integrity and efficiency of research.

Authors:  Simon N Young; George N Anderson
Journal:  J Psychiatry Neurosci       Date:  2010-01       Impact factor: 6.186

3.  Redox reactions of the α-synuclein-Cu(2+) complex and their effects on neuronal cell viability.

Authors:  Chengshan Wang; Lin Liu; Lin Zhang; Yong Peng; Feimeng Zhou
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

Review 4.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

Review 5.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.

Authors:  D A Loeffler; P A LeWitt; P L Juneau; D M Camp; A J DeMaggio; M K Havaich; P E Milbury; W R Matson
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

7.  Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Parkinsons Dis       Date:  2011-10-11

Review 8.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

9.  Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.

Authors:  Satoru Morimoto; Masaki Takao; Hiroyuki Hatsuta; Yasushi Nishina; Tadashi Komiya; Renpei Sengoku; Yuta Nakano; Akiko Uchino; Hiroyuki Sumikura; Yuko Saito; Kazutomi Kanemaru; Shigeo Murayama
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

10.  Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Arian Tavasol; Kimia Jazi; Ramtin Hajibeygi; Sina Shool; Fatemeh Sodeifian; Andis Klegeris; Alyssa McElhinney; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.